July 02, 2025

FDA Approves Ready-to-Infuse Vancomycin

Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.

Conexiant

July 02, 2025

Dengue Threat Grows with Mosquito Surge

Climate change, wildfire aftermath, and lack of a reliable vaccine raise concerns that dengue may become endemic in parts of the U.S. as mosquito season intensifies.

KFF Health News

July 01, 2025

FDA Approves Low-IgA IG Therapy

GAMMAGARD LIQUID ERC is the first ready-to-use liquid immunoglobulin therapy with IgA ≤2 µg/mL for primary immunodeficiency in individuals aged 2 years and older.

Conexiant

June 30, 2025

Breakthrough Device Approvals Outpacing Data

Many FDA-authorized breakthrough therapeutic devices may lack robust clinical testing.

Conexiant

June 26, 2025

First Targeted Therapy Approved for BP

The FDA has approved dupilumab as the first targeted treatment for adults with bullous pemphigoid, showing improved remission rates and reduced corticosteroid use.

Conexiant

June 24, 2025

Exam Shift Spurs National Rights Battle

Democratic AGs push to relocate OB-GYN exams from Texas, citing threats to reproductive and gender-affirming care under state abortion bans.

KFF Health News

June 24, 2025

FDA Approves At-Home Lupus Nephritis Therapy

The FDA has approved a subcutaneous autoinjector of belimumab for at-home treatment of pediatric lupus nephritis.

Conexiant

June 23, 2025

Older Adults Lead Vaccine Comeback

Older Americans are embracing vaccines—backed by new research confirming enhanced safety, disease prevention, and even a potential link to reduced dementia risk.

KFF Health News

June 20, 2025

FDA Approves First Twice-Yearly Injectable PrEP

FDA approved the first biannual injectable PrEP option, Yeztugo (lenacapavir), after studies showed it prevented HIV infection in over 99.9% of participants.

Conexiant